PERTH, Australia – New Australian and European guidelines on managing sexually transmitted diseases (STDs) are driving demand for Speedx Ltd.'s molecular diagnostic that simultaneously detects the Mycoplasma genitalium bacteria and the genetic markers linked to antimicrobial resistance.
PERTH, Australia – Melbourne-based Neuren Pharmaceuticals signed a development and commercialization deal with Acadia Pharmaceuticals Inc. worth up to $465 million for North American rights to trofinetide for Rett syndrome and other indications.
PERTH, Australia – Melbourne-based Neuren Pharmaceuticals signed a development and commercialization deal with Acadia Pharmaceuticals Inc. worth up to $465 million for North American rights to trofinetide for Rett syndrome and other indications.
PERTH, Australia – Mesoblast Ltd. has signed a deal with China's Tasly Pharmaceutical Group that opens up the massive greater China market to the Aussie stem cell company to develop, manufacture and commercialize two of its late-stage allogeneic mesenchymal precursor cell (MPC) candidates for cardiovascular indications.
PERTH, Australia – Mesoblast Ltd. has signed a deal with China's Tasly Pharmaceutical Group that opens up the massive greater China market to the Aussie stem cell company to develop, manufacture and commercialize two of its late-stage allogeneic mesenchymal precursor cell (MPC) candidates for cardiovascular indications.
PERTH, Australia – Draft legislation released by the Turnbull Government on the overhauled R&D Tax Incentive (R&DTI) received an overall positive response from the biotech and med-tech industry, but a few components of the bill are causing concern, industry stakeholders said.
PERTH, Australia – Draft legislation released by the Turnbull Government on the overhauled R&D Tax Incentive (R&DTI) received an overall positive response from the biotech and med-tech industry, but a few components of the bill are causing concern, industry stakeholders said.
